OTHER CURRENT LIABILITIES

9 Months Ended

Sep. 30, 2012

Notes To Consolidated Financial Statement [Abstract]

OTHER CURRENT LIABILITIES

14.       OTHER CURRENT LIABILITIES

Other current liabilities as of September 30, 2012 and December 31, 2011 is comprised of the following(in thousands):

	September 30, 2012		December 31, 2011
Accrued incentives, including SARs liability	$	44,199	$	41,516
Deferred revenue		11,351		13,703
Counterparty Settlement Agreement
liability (see Note 15)		24,925		-
Other accrued expenses		33,962		23,566
	$	114,437	$	78,785

Deferred revenue as of September 30, 2012 and December 31, 2011 is comprised of the following (in thousands):

	September 30, 2012		December 31, 2011
Deferred revenue - aesthetics products, net
of cost of revenue	$	7,694	$	13,349
Deferred revenue - sales into distribution
channel in excess of eight weeks of
projected demand		3,513		212
Other deferred revenue		144		142
	$	11,351	$	13,703

The Company defers revenue, and the related cost of revenue, of its aesthetics products, including DYSPORT®, PERLANE® and RESTYLANE®, until its exclusive U.S. distributor ships the product to physicians. The Company also defers the recognition of revenue for certain sales of inventory into the distribution channel that are in excess of eight (8) weeks of projected demand. The increase in deferred revenue for units in the distribution channel in excess of eight weeks of projected demand during the nine months ended September 30, 2012 was primarily associated with units of ZYCLARA®.